Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid S...
January 20 2021 - 8:05AM
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced it will participate in the New York Academy
of Sciences’ webinar on January 27, 2021 on the endocannabinoid
system as a target for therapeutic agents.
Data about Corbus’ pipeline will be
presented in the following sessions:
- Talk: New Insights into the Resolution of Acute Inflammation in
Humans Provided by -- Lenabasum, a Synthetic Analogue of delta -8-
tetrahydrocannabinol (THC)-11-oic Acid
- Speaker: Derek Gilroy, Ph.D., University College London
- Date and Time: January 27, 2021 at 2:55 PM ET
- Talk: Therapeutic Potential of Targeting Cannabinoid
Type 1 and Type 2 Receptors
- Speaker: Barbara White, M.D., Chief Medical Officer and Head of
Research, Corbus
- Date and Time: January 27, 2021 at 3:55 PM ET
- Oral Abstract Presentation: CRB-317, a Selective
Cannabinoid Receptor Type 2 (CB2) Agonist, Inhibits NLRP3
Inflammasome Activation, Cytokine Production, and Has Activity in a
Model of Gouty Arthritis
- Speaker: Ping Zhang, Ph.D., Principal Scientist, Corbus
- Date and Time: January 27, 2021 at 4:35 PM ET
To register for the webinar or to view the live
webcast, click here.
About the New York Academy of Sciences
The New York of Academy of Sciences is an
independent, not-for-profit organization that since 1817 has been
committed to advancing science for the benefit of society. With
more than 20,000 Members in 100 countries, the Academy advances
scientific and technical knowledge, addresses global challenges
with science-based solutions, and sponsors a wide variety of
educational initiatives at all levels for STEM and STEM related
fields. The Academy hosts programs and publishes content in the
life and physical sciences, the social sciences, nutrition,
artificial intelligence, computer science, and sustainability. The
Academy also provides professional and educational resources for
researchers across all phases of their careers. Please visit us
online at www.nyas.org.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product candidate,
lenabasum, is a novel, oral, selective cannabinoid receptor type 2
(CB2) agonist designed to provide an alternative to
immunosuppressive medications in the treatment of chronic
inflammatory and fibrotic diseases. Lenabasum is currently being
evaluated in dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of other preclinical drug
candidates from its endocannabinoid system platform.
Lenabasum is not approved for the treatment of
any indication. For more information on Corbus’ clinical programs,
please visit here.
For more information, visit http://www.corbuspharma.com/, and
connect with us on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's restructuring,
trial results, product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statements that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's
current beliefs and assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential,” "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors,
including the potential impact of the recent COVID-19 pandemic and
the potential impact of sustained social distancing efforts, on our
operations, clinical development plans and timelines, which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7745 Email:
ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7749 Email:
mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024